VSK Kerala
  • Home
  • വാര്‍ത്ത
    • കേരളം
    • ഭാരതം
    • ലോകം
    • സംഘ വാര്‍ത്തകള്‍
    • സേവന വാര്‍ത്തകള്‍
    • അമൃതമഹോത്സവം
    • ബുള്ളറ്റിൻ
  • English
    • Articles
    • Kerala
    • India
    • World
    • RSS in News
    • Seva News
    • Amrit Mahotsav
  • ലേഖനങ്ങള്‍
  • സംസ്കൃതി
  • വീഡിയോ
  • RSS
    • RSS: Vision and Mission
    • Press Release
    • Resolutions
  • VSK
    • About Us
    • Activities
No Result
View All Result
VSK Kerala
  • Home
  • വാര്‍ത്ത
    • കേരളം
    • ഭാരതം
    • ലോകം
    • സംഘ വാര്‍ത്തകള്‍
    • സേവന വാര്‍ത്തകള്‍
    • അമൃതമഹോത്സവം
    • ബുള്ളറ്റിൻ
  • English
    • Articles
    • Kerala
    • India
    • World
    • RSS in News
    • Seva News
    • Amrit Mahotsav
  • ലേഖനങ്ങള്‍
  • സംസ്കൃതി
  • വീഡിയോ
  • RSS
    • RSS: Vision and Mission
    • Press Release
    • Resolutions
  • VSK
    • About Us
    • Activities
No Result
View All Result
VSK Kerala
No Result
View All Result
Home English

DCGI approves anti-COVID drug developed by DRDO for emergency use

VSK Kerala Desk by VSK Kerala Desk
9 May, 2021
in English
ShareTweetSendTelegram

New Delhi: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.

The DRDO, along with its industry partner DRL, Hyderabad, started the clinical trials to test the safety and efficacy of the drug in COVID-19 patients. In Phase-II trials (including dose ranging) conducted during May to October 2020, the drug was found to be safe in COVID-19 patients and showed significant improvement in their recovery. Phase IIa was conducted in six hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients.

In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalisation of specific vital signs parameters when compared to SoC.

Based on successful results, DCGI further permitted the Phase-III clinical trials in November 2020. The Phase-III clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The detailed data of phase-III clinical trial was presented to DCGI. In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by Day-3 in comparison to SoC, indicating an early relief from Oxygen therapy/dependence.

The similar trend was observed in patients aged more than 65 years. On May 01, 2021, DCGI granted permission for Emergency Use of this drug as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.

The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.

In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of COVID-19 patients.

ShareTweetSendShareShare

Latest from this Category

Islamic extremists disrupt International Yoga Day event in Maldives

There Has Been Deliberate Attempt To Discredit Judiciary: Justice N. Nagaresh On Contemptuous Remarks By PFI Leader

‘One Nation – One Health System is the need of Hour’

Father of minor boy who called for genocide of Hindus and Christians in PFI rally arrested

Strict action should be taken against the organizers of the rally – Kerala High Court

Temples vandalised by miscreants in Guwahati ; Shiva, Ganesha idols uprooted and thrown out of Temple

Load More

Discussion about this post

Latest News

Islamic extremists disrupt International Yoga Day event in Maldives

There Has Been Deliberate Attempt To Discredit Judiciary: Justice N. Nagaresh On Contemptuous Remarks By PFI Leader

‘One Nation – One Health System is the need of Hour’

Father of minor boy who called for genocide of Hindus and Christians in PFI rally arrested

Strict action should be taken against the organizers of the rally – Kerala High Court

Temples vandalised by miscreants in Guwahati ; Shiva, Ganesha idols uprooted and thrown out of Temple

Islamic terrorist Yasin Malik sentenced to life imprisonment in terror funding case

Gyanvapi Case – Fresh plea challenging Places of Worship Act filed in Supreme Court

Load More

Latest Malayalam News

ആകാശത്ത് വിസ്മയമായി അഞ്ച് ഗ്രഹങ്ങളുടെ സംഗമം

തമിഴ്നാട്ടിൽ വീണ്ടും ക്ഷേത്രങ്ങൾക്കുനേരെ ആക്രമണം: വിഗ്രഹങ്ങൾ തകർത്തു

മുംബൈയിൽ ഗുരുകുലം വിദ്യാർത്ഥികൾ ദ്രൗപദീമുർമൂവിന് പിന്തുണയുമായി ചിത്രങ്ങൾ വരയ്ക്കുന്നു

ദ്രൗപദീ മുർമൂ: ആവേശത്തോടെ യുവാക്കളും

നാമനിർദേശപത്രിക സമർപ്പിക്കാൻ ഒപ്പം ബിജെഡി മന്ത്രിമാരും

Load More

©Vishwa Samvada Kendram, Kerala.
Tech-enabled by Ananthapuri Technologies

No Result
View All Result
  • Home
  • വാര്‍ത്ത
    • കേരളം
    • ഭാരതം
    • ലോകം
    • സംഘ വാര്‍ത്തകള്‍
    • സേവന വാര്‍ത്തകള്‍
    • അമൃതമഹോത്സവം
    • ബുള്ളറ്റിൻ
  • English
    • Articles
    • Kerala
    • India
    • World
    • RSS in News
    • Seva News
    • Amrit Mahotsav
  • ലേഖനങ്ങള്‍
  • സംസ്കൃതി
  • വീഡിയോ
  • RSS
    • RSS: Vision and Mission
    • Press Release
    • Resolutions
  • VSK
    • About Us
    • Activities

©Vishwa Samvada Kendram, Kerala.
Tech-enabled by Ananthapuri Technologies